{"version":"https://jsonfeed.org/version/1","title":"Core Delta","home_page_url":"https://core-delta.com","description":"Core Delta","author":{"name":"Core Delta"},"items":[{"id":"https://core-delta.com/insights/f/medtech-valuation-why-the-same-30m-means-two-companies","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/280ccb62-434d-4050-b9cf-19e837c05ff8/blob-f2029d2.png\"/><p>Two medtech companies go out to raise at the same $30M valuation. One closes in six weeks. The other spends six months explaining itself, then re-trades. Same number, same sector, same stage. The difference isn't the val...</p>","url":"https://core-delta.com/insights/f/medtech-valuation-why-the-same-30m-means-two-companies","title":"Medtech valuation: why the same $30M means two companies","summary":"Two medtech companies go out to raise at the same $30M valuation. One closes in six weeks. The other spends six months explaining itself, then re-trades. Same number, same sector, same stage. The difference isn't the val...","date_modified":"2026-07-29T12:21:35Z"},{"id":"https://core-delta.com/insights/f/the-decisions-that-price-your-company","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/280ccb62-434d-4050-b9cf-19e837c05ff8/July%202026%20image.jpg\"/><p>Picture two MedTech startups. Same core technology. Same addressable market. Same burn rate, same team size, comparable IP. One raises its Series A at a $40M post-money valuation. The other, a year later, struggles to cl...</p>","url":"https://core-delta.com/insights/f/the-decisions-that-price-your-company","title":"The Decisions That Price Your Company","summary":"Picture two MedTech startups. Same core technology. Same addressable market. Same burn rate, same team size, comparable IP. One raises its Series A at a $40M post-money valuation. The other, a year later, struggles to cl...","date_modified":"2026-07-01T09:00:00Z"},{"id":"https://core-delta.com/insights/f/why-medtech-startups-fail-on-decision-sequencing-not-science","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/280ccb62-434d-4050-b9cf-19e837c05ff8/Blog%205%20Image.jpg\"/><p>Ask most MedTech founders why startups fail, and the answer is usually technical:\n the science didn’t work, the data wasn’t strong enough, the technology fell short.</p>","url":"https://core-delta.com/insights/f/why-medtech-startups-fail-on-decision-sequencing-not-science","title":"Why MedTech Startups Fail on Decision Sequencing, Not Science","summary":"Ask most MedTech founders why startups fail, and the answer is usually technical:\n the science didn’t work, the data wasn’t strong enough, the technology fell short.","date_modified":"2026-05-01T09:00:00Z"},{"id":"https://core-delta.com/insights/f/why-500000-of-additional-revenue-may-not-increase-valuation","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/280ccb62-434d-4050-b9cf-19e837c05ff8/Blog%204%20Image.webp\"/><p>Revenue growth is often treated as the ultimate proof of progress. So when a business adds $500,000 in annual revenue, the expectation is simple: the company must be worth more.</p>","url":"https://core-delta.com/insights/f/why-500000-of-additional-revenue-may-not-increase-valuation","title":"Why $500,000 of Additional Revenue May Not Increase Valuation","summary":"Revenue growth is often treated as the ultimate proof of progress. So when a business adds $500,000 in annual revenue, the expectation is simple: the company must be worth more.","date_modified":"2026-04-01T09:00:00Z"},{"id":"https://core-delta.com/insights/f/why-owners-and-buyers-often-value-businesses-differently","html_content":"<img src=\"https://img1.wsimg.com/isteam/ip/280ccb62-434d-4050-b9cf-19e837c05ff8/Blog%20Post%203%20Image.png\"/><p>EBITDA Multiples vs. Discounted Cash Flow:</p>","url":"https://core-delta.com/insights/f/why-owners-and-buyers-often-value-businesses-differently","title":"Why Owners and Buyers Often Value Businesses Differently","summary":"EBITDA Multiples vs. Discounted Cash Flow:","date_modified":"2026-03-15T09:00:00Z"},{"id":"https://core-delta.com/insights/f/valuing-pre-revenue-and-early-revenue-medtech-startups","html_content":"<img src=\"https://img1.wsimg.com/isteam/stock/NBl0RVk\"/><p>Valuing Pre-Revenue and Early-Revenue MedTech Startups: A Practical Guide for Founders</p>","url":"https://core-delta.com/insights/f/valuing-pre-revenue-and-early-revenue-medtech-startups","title":" Valuing Pre-Revenue and Early-Revenue MedTech Startups","summary":"Valuing Pre-Revenue and Early-Revenue MedTech Startups: A Practical Guide for Founders","date_modified":"2026-03-01T10:00:00Z"},{"id":"https://core-delta.com/insights/f/the-unique-finance-challenges-medical-device-startups-face","html_content":"<img src=\"https://img1.wsimg.com/isteam/getty/2210069702\"/><p>Medical device startups live in a world that looks nothing like a typical venture-backed software company. Product development cycles are longer. Regulatory risk is real. Commercialization depends on reimbursement, clini...</p>","url":"https://core-delta.com/insights/f/the-unique-finance-challenges-medical-device-startups-face","title":"The Unique Finance Challenges Medical Device Startups Face ","summary":"Medical device startups live in a world that looks nothing like a typical venture-backed software company. Product development cycles are longer. Regulatory risk is real. Commercialization depends on reimbursement, clini...","date_modified":"2026-02-16T00:00:00Z"}]}